Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Microbot Medical Inc.MBOT · Entity 6767 | Director | October 23, 2019 | October 24, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Microbot Medical Inc.
Report date October 23, 2019 · Filed October 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.06 · Expires 2029-10-23 | Direct | 3,952 |
Reported balance
After 2019-10-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-23 · Grant · Acquired 3,952 · Balance 3,952 F1: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on April 23, 2020, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on April 23, 2020, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 23, 2019 Filed Oct 24, 2019 23:10 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 3,952 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001493152-19-015927 · ownership.xml · derivative · entry 1 Waizer Yoav Zvi · CIK 0001689845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,952 Underlying: Common Stock, par value $0.01 per share · 3,952 shares Expires 2029-10-23 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on April 23, 2020, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| January 21, 2019 Filed Jan 23, 2019 22:44 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 2,326 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001493152-19-000863 · ownership.xml · derivative · entry 1 Waizer Yoav Zvi · CIK 0001689845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,326 Underlying: Common Stock, par value $0.01 per share · 2,326 shares Expires 2029-01-21 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on March 4, 2019, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 22:12 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 38,095 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001493152-17-014429 · form4.xml · derivative · entry 1 Waizer Yoav Zvi · CIK 0001689845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,095 Underlying: Common Stock, par value $0.01 per share · 38,095 shares Expires 2027-12-06 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2017 Equity Incentive Plan: (a) on the six month anniversary of the date of grant, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. Read SEC document |
| December 05, 2017 Filed Dec 6, 2017 17:55 UTC | Microbot Medical Inc. MBOT · Entity 6767 | SaleCommon Stock | 10,000 | $1.08 | $10,800.00 |
DisclosureSEC source: 0001493152-17-014245 · form4.xml · nonDerivative · entry 2 Waizer Yoav Zvi · CIK 0001689845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 17:55 UTC | Microbot Medical Inc. MBOT · Entity 6767 | PurchaseCommon Stock | 10,000 | $1.10 | $11,000.00 |
DisclosureSEC source: 0001493152-17-014245 · form4.xml · nonDerivative · entry 1 Waizer Yoav Zvi · CIK 0001689845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.